Thymus cancer treatment with targeted therapy

Thymus cancer treatment with surgery and chemotherapy proved to be leading methods that help to achieve the best results for patients with tumors of early to moderate severity. Still, most relapsed or metastatic cases require additional strategies to achieve sustainable and satisfactory outcomes. Targeted therapy showed promising effects for those patients. It can effectively be used as a primary treatment method or a part of combined treatment. Targeted therapy aims to impact a particular part of the thymus tumor’s supply chain, making it impossible for cancer to develop and grow further. Modern targeted drugs might affect various factors, including specific proteins, genes, receptors, and other elements crucial for normal tumor functioning. Ideally, targeted medicine also should decrease the number of metastatic lesions and primary tumors shrinking, slowly pushing the patient to the point where it’s possible to use surgical methods. Nowadays, oncologists successfully use EGFR inhibitors, c-KIT inhibitors, HDAC inhibition agents, sorafenib, cixutumumab, sunitinib, octreotide, saracatinib, and their combinations as drugs for targeted therapy. The method might be considered the most effective for patients who didn’t achieve satisfactory results during chemotherapy.